Xencor, Inc. (XNCR): Price and Financial Metrics
GET POWR RATINGS... FREE!
XNCR POWR Grades
- Value is the dimension where XNCR ranks best; there it ranks ahead of 72.3% of US stocks.
- The strongest trend for XNCR is in Quality, which has been heading up over the past 177 days.
- XNCR ranks lowest in Growth; there it ranks in the 14th percentile.
XNCR Stock Summary
- XNCR's current price/earnings ratio is 63.65, which is higher than 91.05% of US stocks with positive earnings.
- Of note is the ratio of XENCOR INC's sales and general administrative expense to its total operating expenses; merely 7.57% of US stocks have a lower such ratio.
- Over the past twelve months, XNCR has reported earnings growth of -852.46%, putting it ahead of only 2.05% of US stocks in our set.
- If you're looking for stocks that are quantitatively similar to XENCOR INC, a group of peers worth examining would be FATE, IGMS, NTLA, RLAY, and ARVN.
- XNCR's SEC filings can be seen here. And to visit XENCOR INC's official web site, go to www.xencor.com.
XNCR Valuation Summary
- In comparison to the median Healthcare stock, XNCR's price/earnings ratio is 154.19% higher, now standing at 57.7.
- XNCR's price/sales ratio has moved down 16.8 over the prior 111 months.
Below are key valuation metrics over time for XNCR.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| XNCR | 2023-01-20 | 5.8 | 2.4 | 57.7 | 55.4 |
| XNCR | 2023-01-19 | 5.8 | 2.4 | 58.0 | 55.6 |
| XNCR | 2023-01-18 | 5.7 | 2.3 | 56.6 | 54.3 |
| XNCR | 2023-01-17 | 5.7 | 2.3 | 56.6 | 54.3 |
| XNCR | 2023-01-13 | 5.7 | 2.3 | 56.7 | 54.4 |
| XNCR | 2023-01-12 | 5.6 | 2.3 | 56.0 | 53.7 |
XNCR Growth Metrics
- Its 4 year revenue growth rate is now at -8.82%.
- Its 3 year revenue growth rate is now at 114.13%.
- Its 4 year price growth rate is now at 49.73%.
The table below shows XNCR's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 296.984 | 110.706 | 29.921 |
| 2022-06-30 | 289.368 | 72.851 | 22.489 |
| 2022-03-31 | 326.64 | 18.928 | 108.712 |
| 2021-12-31 | 275.111 | -16.853 | 82.631 |
| 2021-09-30 | 162.949 | -61.559 | -4.121 |
| 2021-06-30 | 178.632 | -26.402 | 23.52 |
XNCR's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- XNCR has a Quality Grade of D, ranking ahead of 9.2% of graded US stocks.
- XNCR's asset turnover comes in at 0.261 -- ranking 167th of 682 Pharmaceutical Products stocks.
- PTGX, MDWD, and ALBO are the stocks whose asset turnover ratios are most correlated with XNCR.
The table below shows XNCR's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.261 | 1 | 0.051 |
| 2021-03-31 | 0.185 | 1 | -0.142 |
| 2020-12-31 | 0.184 | 1 | -0.145 |
| 2020-09-30 | 0.128 | 1 | -0.162 |
| 2020-06-30 | 0.106 | 1 | -0.154 |
| 2020-03-31 | 0.114 | 1 | -0.111 |
XNCR Price Target
For more insight on analysts targets of XNCR, see our XNCR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $53.55 | Average Broker Recommendation | 1.41 (Moderate Buy) |
XNCR Stock Price Chart Interactive Chart >
XNCR Price/Volume Stats
| Current price | $32.50 | 52-week high | $35.92 |
| Prev. close | $31.78 | 52-week low | $19.35 |
| Day low | $31.82 | Volume | 259,400 |
| Day high | $32.72 | Avg. volume | 355,883 |
| 50-day MA | $28.32 | Dividend yield | N/A |
| 200-day MA | $27.22 | Market Cap | 1.95B |
Xencor, Inc. (XNCR) Company Bio
Xencor Inc. is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases and cancer. The company was founded in 1997 and is based in Monrovia, California.
Latest XNCR News From Around the Web
Below are the latest news stories about XENCOR INC that investors may wish to consider to help them evaluate XNCR as an investment opportunity.
Xencor Highlights 2023 Corporate Priorities and Provides Portfolio UpdatesMONROVIA, Calif., January 09, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023 corporate priorities and provided multiple clinical development updates. |
Caris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb® Antibody Drug CandidatesCaris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, and Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced an expansion of their collaboration to research, develop and commercialize novel XmAb® bispecific and multi-specific antibodies directed agai |
Xencor to Present at the 41st Annual J.P. Morgan Healthcare ConferenceMONROVIA, Calif., January 04, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023 at 3:45 p.m. PST. |
12 Best Small-Cap Healthcare Stocks To Buy NowIn this article, we discuss 12 best small-cap healthcare stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Small-Cap Healthcare Stocks to Buy Now. Macroeconomic headwinds and recessionary concerns will not weaken healthcare deals next year after the market experienced resilient mergers and acquisitions in 2022. […] |
Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual MeetingMONROVIA, Calif., December 12, 2022--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced additional clinical data from expansion cohorts in its Phase 1 study of plamotamab, a CD20 x CD3 bispecific antibody, in patients with relapsed or refractory non-Hodgkin lymphomas. Data will be presented by Krish Patel, M.D., Director of the Lymphoma Program at Swedish Cance |
XNCR Price Returns
| 1-mo | 27.85% |
| 3-mo | 10.88% |
| 6-mo | 16.03% |
| 1-year | 0.15% |
| 3-year | -3.82% |
| 5-year | 38.89% |
| YTD | 24.81% |
| 2022 | -35.09% |
| 2021 | -8.04% |
| 2020 | 26.87% |
| 2019 | -4.89% |
| 2018 | 64.96% |
Continue Researching XNCR
Want to see what other sources are saying about Xencor Inc's financials and stock price? Try the links below:Xencor Inc (XNCR) Stock Price | Nasdaq
Xencor Inc (XNCR) Stock Quote, History and News - Yahoo Finance
Xencor Inc (XNCR) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...